Interestingly, erlotinib was equally effective in patient samples with low and high TMB regardless of EGFR status, challenging the conventional view that erlotinib is most effective in EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.